Cybin Inc.
atai Life Sciences has announced results from its Phase 1 Study of DMX-1002 (Ibogaine) for the treatment of opioid use disorder (OUD).
With a rise in clinical trials investigating psychedelics for a number of mental health conditions, the UK’s Parliamentary Office of Science and Technology (POST) has issued...
The Indigenous Medicine Conservation Fund (IMC Fund) took part in the 2023 Parliament of the World’s Religions (PoWR) held at McCormick Place Lakeside Center in Chicago,...
Enveric Biosciences has confirmed it has completed the manufacture of its lead drug candidate – EB-373 – a New Chemical Entity (NCE) designed as a next-generation...
Cybin Inc.
UK-based COMPASS Pathways has secured $285 million in funding through a private placement to support its research in psychedelic medicines.
Researchers at Lund University have developed a new measuring technique to understand what happens to the neurons in rats’ brains when they are given psychedelics.
The first-ever Professional Practice Guidelines for psychedelic therapy in the US have been published by the American Psychedelic Practitioners Association (APPA) and BrainFutures.
PharmAla Biotech Holdings has announced that it has issued a shipment of its GMP LaNeo MDMA to Mind Medicine Australia.